Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 3.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GTF2F1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GTF2F1 also known as General Transcription Factor IIF Subunit 1 plays an important role in transcription initiation. It weighs around 55 kDa and is expressed in various cell types across human tissues. GTF2F1 acts as a part of the transcription preinitiation complex that interacts with RNA polymerase II. This protein consists of distinct domains that mediate its role in facilitating the recruitment of RNA polymerase II to specific gene promoters.
Biological function summary
The General Transcription Factor IIF Subunit 1 (GTF2F1) functions as part of the transcription machinery specifically as a component of the transcription factor IIF (TFIIF) complex. It contributes to the stabilization and proper function of RNA polymerase II during transcription initiation and reinitiation. The TFIIF complex includes other subunits such as GTF2F2 that work together to manage transcription accuracy and processivity. This complex binds to DNA and RNA polymerase II impacting how transcription is executed across the genome.
Pathways
GTF2F1 participates in the RNA polymerase II transcription initiation pathway which is central to the synthesis of mRNA from DNA templates. This pathway involves several other general transcription factors like TFIID. GTF2F1 also influences the positive transcription elongation factor b (P-TEFb) pathway which helps regulate transcription elongation by phosphorylating the RNA polymerase II C-terminal domain. Through these pathways GTF2F1 indirectly associates with numerous gene expression regulatory mechanisms.
Abnormal function or expression of GTF2F1 connects to cancer and neurodegenerative diseases. In cancer dysregulation in transcription may lead to uncontrolled cell proliferation. Other proteins such as TFIID and TFIIB also interact within this context affecting the transcription regulatory landscape. In neurodegenerative diseases disrupted gene expression involving GTF2F1 and its associated complexes may contribute to disease progression linking transcription inaccuracies to cell dysfunction and death.
